



6100 Bristol Parkway | Culver City, CA

### **Expanded Access Policy Statement**

Patients with serious or life-threatening conditions occasionally request access to investigational agents outside of a clinical trial and prior to regulatory approval and commercial availability. These patients seek such access for any number of reasons, including failure of past treatments, intolerable side effects associated with their treatment, or because they do not meet the inclusion criteria for any ongoing clinical trial for their disease.

Programs that allow for such access are known as Expanded Access Programs (EAPs) and are often also referred to as Early Access, Compassionate Use and Emergency Use.

Currently, TORL Biotherapeutics does not have EAPs for any of its investigational agents because we have not yet determined that there is sufficient clinical data to support granting expanded access. If TORL Bio ultimately adopts an EAP for one or more of its investigational agents, this Policy Statement will be updated accordingly. In such event, TORL Bio will ensure that its EAP would comply with applicable legal and regulatory requirements.

Questions regarding this Policy statement should be sent to [info@torlbio.com](mailto:info@torlbio.com). Information regarding TORL Bio's clinical trials, as well as clinical trials and expanded access programs for other potential therapies, can be found on [www.clinicaltrials.gov](http://www.clinicaltrials.gov).